Recent Updates
Recently added Catalysts

KAI-9531

Phase 3

Obesity | Small molecule | Metabolic |Kailera Therapeutics, Inc.|Last Updated: Jul 22, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment3,250
FDA Designations
No designations recorded
Clinical trial landscape

KAI-9531 · 4 trials · 3 indications

Phase 3 2Phase 2 1Phase 1 1
NCT07284979Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesObesity
RECRUITING1,200 Analytics
NCT07284875Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesObesity
RECRUITING2,340 Analytics
PHASE3RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Obesity
NCT072849791,200
Unlock trial analytics
PHASE3RECRUITING
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Obesity
NCT072848752,340
Unlock trial analytics
Study Endpoints
Primary Endpoints
Percent Change From Baseline in Body Weight at Week 76
Baseline, Week 76
Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76
Baseline, Week 76
Percent Change From Baseline in Body Weight at Week 48
Baseline, Week 48
Maximum Observed Concentration (Cmax) of KAI-9531
Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose
Area Under the Concentration-time Curve From 0 to Time of Last Quantifiable Concentration (AUC0-t) of KAI-9531
Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose
Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of KAI-9531
Treatment Period 1, 2 and 3: Pre-dose and up to 672 hours post-dose
Secondary Endpoints
Percentage of Participants with ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight
Baseline, Week 76
Change From Baseline in Waist Circumference
Baseline, Week 76
Change From Baseline in Absolute Body Weight
Baseline, Week 76
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Ribupatide: Dose 1EXPERIMENTALParticipants will receive Dose 1 of ribupatide once weekly.
Ribupatide: Dose 2EXPERIMENTALParticipants will receive Dose 2 of ribupatide once weekly.
SemaglutideACTIVE_COMPARATORParticipants will receive semaglutide once weekly.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo matched to ribupatide once weekly.
Ribupatide: Dose 3EXPERIMENTALParticipants will receive Dose 3 of ribupatide once weekly.
Ribupatide: Dose 4EXPERIMENTALParticipants will receive Dose 4 of ribupatide once weekly.
KAI-9531: Dose 1EXPERIMENTALParticipants will receive Dose 1 of KAI-9531 once weekly.
KAI-9531: Dose 2EXPERIMENTALParticipants will receive Dose 2 of KAI-9531 once weekly.
KAI-9531: Dose 3EXPERIMENTALParticipants will receive Dose 3 of KAI-9531 once weekly.
KAI-9531: Dose 4EXPERIMENTALParticipants will receive Dose 4 of KAI-9531 once weekly.
KAI-9531: Abdomen Injection SiteEXPERIMENTALParticipants will receive KAI-9531 as a SC injection into the abdomen on Day 1 of either Treatment Period 1, 2 or 3.
KAI-9531: Thigh Injection SiteEXPERIMENTALParticipants will receive KAI-9531 as a SC injection into the thigh on Day 1 of either Treatment Period 1, 2 or 3.
KAI-9531: Upper Arm Injection SiteEXPERIMENTALParticipants will receive KAI-9531 as a SC injection into the upper arm on Day 1 of either Treatment Period 1, 2 or 3.
Interventions
NameTypeDescription
RibupatideDRUGSC Injection
SemaglutideDRUGSC Injection
PlaceboDRUGSC Injection
KAI-9531DRUGSC Injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites53

Key Inclusion Criteria: * BMI ≥35 kilograms per square meter (kg/m\^2). * History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months. Key Exclusion Criteria: * Current diagnosis or history of diabetes mellitus. * Started medicati...

Countries:United StatesAustraliaBulgariaPolandUnited KingdomArgentinaCzechiaGermanyNew ZealandSpain
Unlock Eligibility Criteria
Competitive Landscape -Obesity 196 trials

Top 20 of 33 competitors

CompanyTickerTrialsLead PhaseDrugs
Amgen Inc.AMGN8PHASE3Maridebart cafraglutide
Eli Lilly and CompanyLLY42PHASE3Retatrutide
Novo Nordisk A/S Sponsored ADR Class BNVO46PHASE3Cagrilintide, Semaglutide
Rhythm Pharmaceuticals, Inc.RYTM7PHASE3Setmelanotide
Regeneron Pharmaceuticals, Inc.REGN3PHASE3Mibavademab
Pfizer Inc.PFE2PHASE3PF-08653944
Vanda Pharmaceuticals Inc.VNDA1PHASE3Tradipitant
Kailera Therapeutics, Inc.KLRA4PHASE3KAI-9531
AstraZeneca PLCAZN3PHASE2AZD6234
Structure Therapeutics, Inc. Sponsored ADRGPCR3PHASE2Undisclosed
PfizerMTSR3PHASE3MET097
Biohaven Ltd.BHVN1PHASE2Taldefgrobep Alfa
Skye Bioscience, Inc.SKYE1PHASE2Nimacimab, semaglutide
Palatin Technologies, Inc.PTN1PHASE2bremelanotide, tirzepatide
Veru IncVERU1PHASE2Enobosarm, Semaglutide weekly
Arrowhead Pharmaceuticals, Inc.ARWR2PHASE1ARO-INHBE, Tirzepatide
Alnylam Pharmaceuticals, IncALNY1PHASE1ALN-2232, Tirzepatide
Gilead Sciences, Inc.GILD1PHASE1GS-4571, Omeprazole
MBX Biosciences, Inc.MBX1PHASE1MBX 4291
AbbVie, Inc.ABBV1PHASE1ABBV-295
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMJul 22, 2026NCT07284875Enrollment: 1800 → 2340
MEDIUMJul 22, 2026NCT07284979primaryCompletionDate: changed
MEDIUMJul 22, 2026NCT07284875Enrollment: 1800 → 2340
MEDIUMJul 22, 2026NCT07284979primaryCompletionDate: changed
LOWJun 18, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 18, 2026NCT07284979lastUpdatePostDate: changed
LOWJun 18, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 18, 2026NCT07284979lastUpdatePostDate: changed
LOWJun 18, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 18, 2026NCT07284979lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284979lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284979lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284875lastUpdatePostDate: changed
LOWJun 8, 2026NCT07284979lastUpdatePostDate: changed
LOWMay 26, 2026NCT07458269primaryCompletionDate: changed
LOWMay 26, 2026NCT07284979primaryCompletionDate: changed
LOWMay 26, 2026NCT07284875primaryCompletionDate: changed
LOWMay 24, 2026NCT07458269studyFirstPostDate: changed